2012

• Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012), The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer. 75(2), 248-254. [Abstract]
• Jaiswal, R., Gong, J., Sambasivam, S., Combes, V., Mathys, J., Davey, R., Grau, G., Bebawy, M. (2012), Microparticle-associated nucleic acids mediate trait dominance in cancer. The FASEB Journal. 26(1), 420-429. [Abstract]

2009

• Stordal, B., Davey, R. (2009), A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Current Cancer Drug Targets. 9(3), 354-365. [Abstract]
• Stordal, B., Davey, R. (2009), ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair. Cancer chemotherapy and pharmacology. 63(4), 661-72. [Abstract]
• Bromley, R., Oliver, L., Davey, R., Harvie, R., Baldock, C. (2009), Predicting the clonogenic survival of A549 cells after modulated x-ray irradiation using the linear quadratic model. Physics in medicine and biology. 54(2), 187-206. [Abstract]
• Stordal, B., Davey, R. (2009), Regrowth resistance: low-level platinum resistance mediated by rapid recovery from platinum-induced cell-cycle arrest. In: Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications. (pp.171-176).United States: Humana Press.
• Stordal, B., Pavlakis, N., Davey, R. (2009), A systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy. In: Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications. (pp.225-230).United States: Humana Press.

2008

• Janneh, O., Hartkoorn, R., Jones, E., Owen, A., Ward, S., Davey, R., Back, D., Khoo, S. (2008), Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. British journal of pharmacology. 155(6), 875-883. [Abstract]
• Stordal, B., Davey, R. (2008), Platinum resistance needs the mythbusters. Toxicology letters. , 230. [Abstract]
• Stordal, B., Davey, R. (2008), A 39 kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome. IUBMB Life. 60(3), 180-184. [Abstract]

2007

• Stordal, B., Pavlakis, N., Davey, R. (2007), A systematic review of platinum and taxane resistance from bench to clinic: An inverse relationship. Cancer treatment reviews. 33(8), 688-703. [Abstract]
• Murphy, S., Davey, R., Gu, X., Haywood, M., McCann, L., Mather, L., Boyle, F. (2007), Enhancement of cisplatin efficacy by thalidomide in a 9L rat gliosarcoma model. Journal of neuro-oncology. 85(2), 181-9. [Abstract]
• McCann, L., Haywood, M., Ren, B., Simpson, A., Guilhaus, M., Wasinger, V., Raftery, M., Davey, R. (2007), Identification of Vascular Surface Proteins by in Vivo Biotinylation: A Method Sufficiently Sensitive To Detect Changes in Rat Liver 2 Weeks after Partial Hepatectomy. Journal of proteome research. 6(8), 3108-13. [Abstract]
• Stordal, B., Pavlakis, N., Davey, R. (2007), Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer treatment reviews. 33(4), 347-57. [Abstract]
• Murphy, S., Boyle, F., Davey, R., Gu, X., Mather, L. (2007), Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. The Journal of pharmacy and pharmacology. 59(1), 105-114. [Abstract]